文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

乳腺化生性癌:单中心病例系列及文献复习。

Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature.

机构信息

Department of Clinical Therapeutics, Medical School of National and Kapodistrian University of Athens, "Alexandra" General Hospital of Athens, 115 28 Athens, Greece.

Department of Physiology, Medical School of National and Kapodistrian University of Athens, 115 28 Athens, Greece.

出版信息

Med Sci (Basel). 2023 May 19;11(2):35. doi: 10.3390/medsci11020035.


DOI:10.3390/medsci11020035
PMID:37218987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10204473/
Abstract

Metaplastic carcinoma of the breast (MpBC) is a very rare and aggressive type of breast cancer. Data focusing on MpBC are limited. The aim of this study was to describe the clinicopathological features of MpBC and evaluate the prognosis of patients with MpBC. Eligible articles about MpBC were identified by searching CASES SERIES gov and the MEDLINE bibliographic database for the period of 1 January 2010 to 1 June 2021 with the keywords metaplastic breast cancer, mammary gland cancer, neoplasm, tumor, and metaplastic carcinoma. In this study, we also report 46 cases of MpBC stemming from our hospital. Survival rates, clinical behavior, and pathological characteristics were analyzed. Data from 205 patients were included for analysis. The mean age at diagnosis was 55 (14.7) years. The TNM stage at diagnosis was mostly stage II (58.5%) and most tumors were triple negative. The median overall survival was 66 (12-118) months, and the median disease-free survival was 56.8 (11-102) months. Multivariate Cox regression analysis revealed that surgical treatment was associated with decreased risk of death (hazard ratio 0.11, 95% confidence interval 0.02-0.54, = 0.01) while advanced TNM stage was associated with increased risk of death (hazard ratio 1.5, 95% confidence interval 1.04-2.28, = 0.03). Our results revealed that surgical treatment and TNM stage were the only independent risk factors related to patients' overall survival.

摘要

乳腺化生性癌(MpBC)是一种非常罕见且侵袭性强的乳腺癌。目前针对 MpBC 的数据有限。本研究旨在描述 MpBC 的临床病理特征,并评估 MpBC 患者的预后。通过在 2010 年 1 月 1 日至 2021 年 6 月 1 日期间在 CASES SERIES gov 和 MEDLINE 书目数据库中搜索关键词包括“metaplastic breast cancer”、“mammary gland cancer”、“neoplasm”、“tumor”和“metaplastic carcinoma”,确定了关于 MpBC 的符合条件的文章。在本研究中,我们还报告了来自我们医院的 46 例 MpBC 病例。分析了生存率、临床行为和病理特征。共纳入 205 例患者进行分析。诊断时的平均年龄为 55(14.7)岁。诊断时的 TNM 分期主要为 II 期(58.5%),大多数肿瘤为三阴性。总生存期的中位数为 66(12-118)个月,无病生存期的中位数为 56.8(11-102)个月。多因素 Cox 回归分析显示,手术治疗与降低死亡风险相关(风险比 0.11,95%置信区间 0.02-0.54, = 0.01),而晚期 TNM 分期与死亡风险增加相关(风险比 1.5,95%置信区间 1.04-2.28, = 0.03)。我们的结果表明,手术治疗和 TNM 分期是与患者总生存相关的唯一独立危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/4f7a58b74cda/medsci-11-00035-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/8a39a3b7fb3c/medsci-11-00035-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/9f9b47cdebcb/medsci-11-00035-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/a5dd8bd9a698/medsci-11-00035-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/4f7a58b74cda/medsci-11-00035-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/8a39a3b7fb3c/medsci-11-00035-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/9f9b47cdebcb/medsci-11-00035-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/a5dd8bd9a698/medsci-11-00035-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524b/10204473/4f7a58b74cda/medsci-11-00035-g004.jpg

相似文献

[1]
Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature.

Med Sci (Basel). 2023-5-19

[2]
Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.

Breast Cancer Res Treat. 2018-10-19

[3]
Clinical Characteristics and Prognosis of Metaplastic Breast Cancer Compared with Invasive Ductal Carcinoma: A Propensity-Matched Analysis.

Cancers (Basel). 2023-3-2

[4]
The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.

Breast Cancer Res Treat. 2023-7

[5]
Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.

Pathol Res Pract. 2024-1

[6]
Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.

World J Surg Oncol. 2013-6-6

[7]
[Effect of postmastectomy radiotherapy on survival outcomes of patients with metaplastic breast cancer].

Nan Fang Yi Ke Da Xue Xue Bao. 2021-11-20

[8]
Clinicopathological features of metaplastic breast carcinoma.

Adv Clin Exp Med. 2018-4

[9]
Radiologic Findings of a Rare Subtype of Invasive Breast Cancer with Poor Prognosis: Metaplastic Carcinoma of the Breast.

Curr Med Imaging Rev. 2019

[10]
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Oncologist. 2018-8-23

引用本文的文献

[1]
Pulmonary tumor with osteosarcomatous and chondrosarcomatous components: The differential diagnosis.

Tzu Chi Med J. 2025-4-4

[2]
Metaplastic breast carcinoma: a rare and aggressive entity.

Ann Med Surg (Lond). 2025-1-9

[3]
Metaplastic carcinoma of the breast containing three histological components: a case report.

Front Oncol. 2024-12-19

[4]
Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study.

Acta Oncol. 2024-8-4

[5]
Better Local Disease Control With Mastectomy in Metaplastic Breast Carcinoma: Findings of a Retrospective Cohort.

Cureus. 2024-6-2

[6]
Translational Aspects in Metaplastic Breast Carcinoma.

Cancers (Basel). 2024-4-7

[7]
Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience.

Oncol Lett. 2024-3-8

[8]
Sarcomatoid Carcinoma of the Breast: An Unusual Clinical Presentation.

Cureus. 2024-1-21

[9]
Epoxy- versus Glutaraldehyde-Treated Bovine Jugular Vein Conduit for Pulmonary Valve Replacement: A Comparison of Morphological Changes in a Pig Model.

Biomedicines. 2023-11-20

本文引用的文献

[1]
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

J Clin Oncol. 2021-9-10

[2]
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy.

Front Oncol. 2021-6-8

[3]
The Role of Adjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Competing Risk Analysis of the SEER Database.

Front Oncol. 2021-4-26

[4]
Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.

Front Endocrinol (Lausanne). 2021

[5]
Metaplastic breast cancer with chondroid differentiation-case report and literature review.

J Surg Case Rep. 2021-4-22

[6]
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.

BMJ. 2021-3-29

[7]
Metaplastic breast cancer: Treatment and prognosis by molecular subtype.

Transl Oncol. 2021-5

[8]
Metaplastic squamous cell breast cancer: A case report and treatment strategy during covid-19 pandemic.

Int J Surg Case Rep. 2021-2

[9]
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

J Clin Oncol. 2021-5-1

[10]
Cancer Statistics, 2021.

CA Cancer J Clin. 2021-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索